NCCN Pharmacy Updates: Management of Immunotherapy-Associated Oral Toxicities
Oncology pharmacists are vital members of the oncology team with specialized knowledge of anticancer therapy and can help navigate therapeutic interventions, contributing to selection, dosing, monitoring, evaluation, and education of medications to improve oral immune-related adverse event outcomes.
Category
  • Management of Immunotherapy-Related Toxicities
Format
  • Live Webinar
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Event date June 10, 2024
NCCN Pharmacy Updates: Hematopoietic Cell Transplantation - An Overview of Hematopoietic Cell Mobilization
It is important for practitioners to understand what factors influence successful stem cell mobilization in preparation for a transplant. They should also be familiar with the agents used in this process.
Category
  • Hematopoietic Cell Transplantation
Format
  • Live Webinar
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Event date July 29, 2024
NCCN Pharmacy Updates: Navigating the Challenging Treatment Landscape for HIV-Associated, Non-AIDS Defining Cancers
The incidence of non-AIDS-defining cancers (NADCs) in HIV-positive patients is increasing, and pharmacists should understand and apply pharmacokinetic parameters in order to identify potential interactions and recommend change in therapy or modifications in dosing and/or administration to aid medical oncologists in choosing the right drug at the right dose given at the right time.
Category
Format
  • Live Webinar
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Event date August 6, 2024
NCCN Pharmacy Updates: What Grade Are You In? The Role of Targeted Therapy in Pediatric Diffuse High-Grade Gliomas
Targeted therapy is a relatively novel treatment approach to pediatric high-grade gliomas. Identifying specific molecular targets with correspondingly effective agents substantially benefits the treatment landscape and broadens therapeutic options in both the adjuvant therapy and recurrent or progressive disease setting.
Category
  • Glioma
Format
  • Live Webinar
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Event date August 30, 2024